Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Talabostat.

Charles Casey Cunningham1

  • 1Mary Crowley Medical Research Center, Dallas, Texas 75201, USA. ccunningham@mcmrc.com

Expert Opinion on Investigational Drugs
|August 24, 2007
PubMed
Summary
This summary is machine-generated.

Talabostat mesilate, a dipeptidyl peptidases inhibitor, uniquely targets tumors via dual mechanisms. It shows significant anti-cancer activity, including complete responses in lung cancer and melanoma patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Talabostat mesilate is an orally active inhibitor of dipeptidyl peptidases.
  • It specifically targets tumor-associated fibroblast activation protein.
  • Talabostat possesses a unique dual mechanism of action in cancer treatment.

Purpose of the Study:

  • To investigate the anti-cancer properties of talabostat mesilate.
  • To elucidate the dual mechanism of action of talabostat.
  • To evaluate the clinical efficacy of talabostat in cancer patients.

Main Methods:

  • Talabostat mesilate was administered orally.
  • Inhibition of dipeptidyl peptidases was assessed.
  • Upregulation of cytokines and chemokines was analyzed.

Related Experiment Videos

  • Clinical trials were conducted in patients with non-small-cell lung cancer and malignant melanoma.

    • Main Results:

    • Talabostat mesilate demonstrated specific inhibition of dipeptidyl peptidases, including tumor-associated fibroblast activation protein.
    • It stimulated the upregulation of cytokines and chemokines, inducing a tumor-specific host immune response.
    • Clinical trials showed significant activity, with complete responses observed in patients with non-small-cell lung cancer and malignant melanoma.

    Conclusions:

    • Talabostat mesilate exhibits a unique dual mechanism of action for cancer therapy.
    • Its ability to inhibit dipeptidyl peptidases and stimulate anti-tumor immunity contributes to its efficacy.
    • Talabostat mesilate represents a promising therapeutic agent for non-small-cell lung cancer and malignant melanoma.